Hongyu Kong1, Qiongwen Zhang2, Yunhui Zeng1, Hong Wang1, Mengqian Wu1, Tianying Zheng1, Yanzhang Zeng1, Huashan Shi2. 1. Clinical Medicine (Eight-Year Program), West China School of Medicine, Sichuan University Chengdu, Sichuan, PRC. 2. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medicine School, Sichuan University Chengdu, Sichuan, PRC ; State Key Laboratory of Biotherapy and Department of Head and Neck Oncology, West China Hospital, West China Medical School, Sichuan University Chengdu, Sichuan, PRC.
Abstract
PURPOSE: The prognostic value of the expression of STAT3/phosphorylated-STAT3 on survival for cancer patients remains controversial. We performed a meta-analysis of the published literature in this field to identify its impact. METHODS: We conducted a meta-analysis of 26 studies (n=3877 patients) that evaluated the relationship between the prognostic value and the expression of STAT3/phosphorylated-STAT3 in 15 different kinds of carcinomas. Studies evaluated the correlation between STAT3/phosphorylated-STAT3, which detected mostly by immunohistochemistry and western blot, and clinical staging, overall survival (OS) and disease free survival (DFS) were included. The impact of STAT3 and phosphorylated-STAT3 was analyzed separately. RESULTS: A total of 26 studies (14 for STAT3 and 16 for phosphorylated-STAT3), comprising 3877 patients, were included for meta-analysis. The expression of STAT3 was strongly associated with a poor impact on overall survival (OS) in all eligible studies [hazard ratio (HR)=2.91, (95% confidence interval (CI), 1.91-4.42)], while a significant association was shown between the expression of phosphorylated-STAT3 and patients' outcome [HR=1.53, (95% CI, 0.86-2.70)]. No significant effect was shown between the expression of STAT3/phosphorylated-STAT3 and clinical staging, neither with DFS. CONCLUSION: High expression of STAT3 seems to be associated with poor OS in patients with carcinomas, while phosphorylated-STAT3 does not.
PURPOSE: The prognostic value of the expression of STAT3/phosphorylated-STAT3 on survival for cancerpatients remains controversial. We performed a meta-analysis of the published literature in this field to identify its impact. METHODS: We conducted a meta-analysis of 26 studies (n=3877 patients) that evaluated the relationship between the prognostic value and the expression of STAT3/phosphorylated-STAT3 in 15 different kinds of carcinomas. Studies evaluated the correlation between STAT3/phosphorylated-STAT3, which detected mostly by immunohistochemistry and western blot, and clinical staging, overall survival (OS) and disease free survival (DFS) were included. The impact of STAT3 and phosphorylated-STAT3 was analyzed separately. RESULTS: A total of 26 studies (14 for STAT3 and 16 for phosphorylated-STAT3), comprising 3877 patients, were included for meta-analysis. The expression of STAT3 was strongly associated with a poor impact on overall survival (OS) in all eligible studies [hazard ratio (HR)=2.91, (95% confidence interval (CI), 1.91-4.42)], while a significant association was shown between the expression of phosphorylated-STAT3 and patients' outcome [HR=1.53, (95% CI, 0.86-2.70)]. No significant effect was shown between the expression of STAT3/phosphorylated-STAT3 and clinical staging, neither with DFS. CONCLUSION: High expression of STAT3 seems to be associated with poor OS in patients with carcinomas, while phosphorylated-STAT3 does not.
Authors: Mustafa Benekli; Zheng Xia; Kathleen A Donohue; Laurie A Ford; Lynda A Pixley; Maria R Baer; Heinz Baumann; Meir Wetzler Journal: Blood Date: 2002-01-01 Impact factor: 22.113
Authors: Andreas Widschwendter; Sibylle Tonko-Geymayer; Thomas Welte; Günter Daxenbichler; Christian Marth; Wolfgang Doppler Journal: Clin Cancer Res Date: 2002-10 Impact factor: 12.531
Authors: L Jin; R Q Yuan; A Fuchs; Y Yao; A Joseph; R Schwall; S J Schnitt; A Guida; H M Hastings; J Andres; G Turkel; P J Polverini; I D Goldberg; E M Rosen Journal: Cancer Date: 1997-08-01 Impact factor: 6.860